Toronto Dominion Bank Buys Shares of 340,974 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Toronto Dominion Bank purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 340,974 shares of the company's stock, valued at approximately $13,162,000. Toronto Dominion Bank owned about 0.57% of Protagonist Therapeutics at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Covestor Ltd boosted its stake in shares of Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock valued at $63,000 after purchasing an additional 1,612 shares during the period. KBC Group NV boosted its holdings in Protagonist Therapeutics by 54.4% in the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after acquiring an additional 737 shares in the last quarter. New Vernon Capital Holdings II LLC purchased a new position in Protagonist Therapeutics during the 4th quarter valued at $118,000. Nisa Investment Advisors LLC raised its holdings in Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after purchasing an additional 295 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter worth about $211,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 1,756 shares of the company's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the transaction, the chief financial officer now owns 61,065 shares in the company, valued at approximately $2,808,990. This represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Arturo Md Molina sold 30,514 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the sale, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. The trade was a 26.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 61,173 shares of company stock valued at $3,461,180 over the last 90 days. Corporate insiders own 4.90% of the company's stock.

Protagonist Therapeutics Stock Down 0.5%

Shares of NASDAQ:PTGX traded down $0.25 on Friday, hitting $45.66. 486,198 shares of the company traded hands, compared to its average volume of 879,690. The stock has a 50 day simple moving average of $46.04 and a 200-day simple moving average of $42.60. The company has a market cap of $2.83 billion, a PE ratio of 17.17 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 52 week low of $27.00 and a 52 week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.31. The company had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Wedbush restated an "outperform" rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a research note on Friday, March 28th. The Goldman Sachs Group reduced their price target on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, February 24th. Truist Financial raised their price objective on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a research report on Tuesday, March 11th. Finally, BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $65.44.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.